ABL Diagnostics SA (ABLD) Stock Statistics & Valuation Metrics

ABL Diagnostics SA has a market cap or net worth of €40.29M. The enterprise value is €35.86M.

ABL Diagnostics SA has 16,114,656 shares outstanding. The number of shares has decreased by -2.65% in one year.

ABL Diagnostics SA’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.92%.

The current PE Ratio of ABL Diagnostics SA is ―. ABL Diagnostics SA’s PEG ratio is 0.00.

In the last 12 months, ABL Diagnostics SA had revenue of 0.00 and earned -140.70K in profits. Earnings per share was -0.56.

In the last 12 months, operating cash flow was -139.20K and capital expenditures 0.00, giving a free cash flow of -139.20K billion.

ABL Diagnostics SA pays an annual dividend of €0.11, resulting in a dividend yield of ―

ABL Diagnostics SA upcoming earnings date is May 11, 2026, Before Open (Confirmed).

ABL Diagnostics SA as a current ratio of ―, with Debt / Equity ratio of 0.01%

In the past 12 months, ABL Diagnostics SA has paid 38.09K in taxes.

ABL Diagnostics SA EV to EBITDA ratio is -7.44, with an EV/FCF ratio of 38.86.

ABL Diagnostics SA has €7.00M in cash and marketable securities with €180.00 in debt, giving a net cash position of €7.00M billion.

Gross margin is 0.00%, with operating margin of ―, and net profit margin of ―.

The average price target for ABL Diagnostics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―